L-Leucine
|
Basic information |
| Metabolite name | L-Leucine |
 | HMDB0000687 |
 |
C00123 |
 |
6106 |
| Synonyms | Leurine; |
| No. of studies | 75 |
|
Basic information |
| Metabolite name | L-Leucine |
| HMDB0000687 |
|
C00123 |
|
6106 |
| Synonyms | Leurine; |
| No. of studies | 75 |
|
Relationship between L-Leucine and depression (count: 75) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M007 | Type1 | CRS group vs. control group | Plasma | Wistar rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M066 | Type1 | CUMS vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M070 | Type1 | depressed group vs. non-depressed group | Urine | Human | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Urine | Cynomolgus monkey | Up |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Down |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M1048 | Type1 | adult high-fat diet group vs. adult control group | Liver | CD-1 mouse | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Liver | CD-1 mouse | Up |
| Study M1056 | Type2 | maternal separation + beraprost group vs. maternal separation group | Serum | Sprague-Dawley rat | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M1071 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, female offspring | Faece | ICR mouse | Down |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M132 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M140 | Type2 | CUMS + paroxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M457 | Type2 | CUMS + D6 doses of PBR group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M510 | Type1 | HSD group vs. control group | Serum | Human | Up |
| Study M510 | Type1 | LQS group vs. control group | Serum | Human | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M553 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Down |
| Study M671 | Type1 | CUMS group vs. control group | Striatum | Sprague-Dawley rat | Up |
| Study M715 | Type1 | MDD group vs. control group | Faece | Human | Up |
| Study M750 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M830 | Type1 | corticosterone group vs. control group | Brain | Swiss mouse | Down |
| Study M830 | Type2 | corticosterone + acupoint catgut embedding group vs. corticosterone group | Brain | Swiss mouse | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M847 | Type2 | CUMS + Bupleuri Radix group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M877 | Type1 | depressed COPD group vs. COPD group | Plasma | Human | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M956 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |